๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› NSCLC
Clinical trial register · United Kingdom · industry-sponsored

NSCLC Trials in the UK

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 2852 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
2852
Studies in scope
industry-sponsored, all four open statuses
1378
Recruiting now
open to new participants
540
Lead sponsors
across recruiting studies
Top sites
London 5 Manchester 3 Newcastle upon Tyne 1 Truro 1 Aberdeen 1
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Pfizer1 AstraZeneca1 Merck Sharp & Dohme LLC1 iOnctura1 Ellipses Pharma1
Site city
London5 Manchester3 Newcastle upon Tyne1 Truro1 Aberdeen1
All 17 cities
Target enrolment
to
6 of 2852 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
Revolution Medicines, Inc.
Phase 3
590
London, Liverpool, Sutton, Manchester
2025-05-06
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
Merck Sharp & Dohme LLC
Phase 3
851
Londonderry, Torquay, London, Nottingham
2024-06-10
Active, closed
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266NSCLC
AstraZeneca
Phase 3
1,350
Aberdeen, Cambridge, Cardiff, Cheltenham, Edinburgh, London, Manchester, Middlesbrough
2022-12-29
Recruiting
A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies
NCT05443126NSCLC
Ellipses Pharma
Phase 1/2
265
London, Manchester, Sheffield
2022-09-30
Active, closed
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
NCT05059522Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer
Pfizer
Phase 3
77
London, Newcastle upon Tyne, Truro
2021-09-29
Active, closed
A Study to Assess a PI3Kฮด Inhibitor (IOA-244) in Patients With Metastatic Cancers
NCT04328844Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC, Myelofibrosis
iOnctura
Phase 1
210
Glasgow
2020-02-25
Rows per page Showing 1–6 of 6
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 18 September 2026. https://priyalifescience.com/clinical-trials-uk/condition/nsclc

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.